Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Inclusion criteria : * Metastatic hormone refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen * Disease Progression during or after docetaxel-containing regimen for mHRPC * Surgical or medical castration * Patient is ≥ 18 years and ≤ 75 years of age * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate bone marrow, liver, and renal function: Neutrophils\> 1500 /mm3; Hemoglobin \> 10 g/dL; Platelets \> 100 x109/L; Bilirubin \< Upper Normal Limit (ULN); Serum Glutamate Oxaloacetate Transaminase (Aspartate Aminotransferase)/SGOT (AST) \< 1.5xULN; Serum Glutamate Pyruvate Transaminase (Alanine Aminotransferase)/SGPT (ALT) \< 1.5xULN; Creatinine \< 1.5xULN. In case of creatinine \> 1.0 x ULN and \< or = 1.5 x ULN, calculated creatinine clearance according to CKD-EPI formula should be \> or = 60 ml/min. * Written informed consent must be obtained prior to any study related procedures Exclusion criteria: * Prior radiotherapy to ≥ 40% of bone marrow * Previous treatment with cabazitaxel (Jevtana®) * Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * Active grade ≥2 peripheral neuropathy * Active grade ≥2 stomatitis * Active infection requiring systemic antibiotic or anti-fungal medication * Active cancer (other than mHRPC) including prior malignancy from which the patient has been disease-free for ≤5 years * Known brain or leptomeningeal involvement * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus) * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a 2 weeks wash-out period is necessary for patients who are already on these treatments). Participation in any other clinical trial with any investigational drug * Patient with reproductive potential not implementing accepted and effective method of contraception The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.